REMOVAB DIN 02385732
Health Canada record
| Active ingredient(s) | CATUMAXOMAB 0.1 MG |
|---|---|
| Dosage form | Solution |
| Route | Intraperitoneal |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | L01FX03 CATUMAXOMAB |
| Original market date | |
| Current status date | 22-Feb-2018 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CATUMAXOMAB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02385724 | REMOVAB | FRESENIUS BIOTECH GMBH | Solution | CATUMAXOMAB 0.1 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 13275 | 2012-05-11 | New Drug Submission (NDS) |